Due to the high prevalence of concurrent Aβ pathology in LBD, blood‐based biomarkers for AD perform less well discriminating AD from LBD (including plasma p‐tau and Aβ assays, which are generally less accurate than p‐tau).32, 33, 34. Here, MAPT is linked to Alzheimer disease.